Search

ALS CANADA AWARDS $3 MILLION FOR 12 NEW RESEARCH PROJECTS TO HELP MAKE AMYOTROPHIC LATERAL SCLEROSIS (ALS) A TREATABLE, NOT TERMINAL DISEASE 2017 funding competition completes $20 million research partnership with the Brain Canada Foundation following the Ice Bucket Challenge TORONTO, November 22,...

Affecting at least 14,000 Americans, amyotrophic lateral sclerosis (ALS) is a paralyzing and highly fatal neurodegenerative disorder for which there are no effective treatments. Scientists peered inside neurons and watched the workings of annexin A11, a gene linked to a rare form of ALS. They found...

Together with the Brain Canada Foundation, the ALS Society of Canada is excited to announce the continuation of their much-valued partnership with a $1-million Discovery Grants competition – launching today! Since 2014, ALS Canada’s partnership with Brain Canada has resulted in nearly $20 million...

2018 funding competition with Brain Canada results in $720,000 for six trainee awards – more trainee awards in a single year than ever before TORONTO, December 13, 2018 – The ALS Society of Canada (ALS Canada), together with Brain Canada, today announced $720,000 in funding for six new trainee...

Project Overview Bacteria involved in gum disease can be found in the brains of people with Alzheimer’s disease and dementia. These bacteria help release toxins into different tissues, including the brain. And these toxins, in turn, increase amyloid beta in the brain, contributing to Alzheimer’s...

A new study gives Canadians the opportunity to test for the disease and provide their perspective on how the results impacted their lives Over half a million Canadians are currently living with Alzheimer’s disease or a related form of dementia, and with a rapidly aging population, that number is...

Researchers can apply for one of Canada’s largest dementia research funding opportunities Each year, the Alzheimer Society Research Program funds the best and brightest dementia researchers across Canada by providing millions of dollars in awards and grants. This year’s competition is now open....

LONDON and DURHAM, N.C., Oct. 29, 2018 /PRNewswire/ — AMO Pharma Limited (“AMO Pharma”), a privately held biopharmaceutical company focusing on rare, childhood onset neurogenetic disorders with limited or no treatment options, recently announced an update on results of the recently-completed TIDE...

We know that Alzheimer’s disease is caused by the clumping together of misfolded proteins in the brain, specifically two proteins called amyloid beta and tau. Project Overview We know that Alzheimer’s disease is caused by the clumping together of misfolded proteins in the brain, specifically two...